Pneumology Service, Hospital Lucus Augusti, Lugo, Spain.
Pneumology Service, Hospital Comarcal de Laredo, Cantabria, Spain.
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1214-1221.e3. doi: 10.1016/j.jaip.2018.10.017. Epub 2018 Oct 25.
The minimum controlling dose of treatment must be established in patients with asthma, but the outcome of step-down is unpredictable.
To identify factors associated with risk of control loss when stepping down asthma treatment and to develop a score to predict this risk.
A prospective, multicenter study including adults with well-controlled asthma was performed. Treatment was stepped up or stepped down over a 12-month period to maintain asthma control. We determined associations between clinical and functional variables and step-down failure. Finally, we derived a score to predict loss of control in 1 cohort and validated it in an independent cohort.
The derivation cohort consisted of 228 patients; 218 completed at least 1 step-down episode and a total of 495 step-down episodes were evaluated. A medical-record documented postbronchodilator spirometry result of <70% forced expiratory volume in 1 second (FEV)/forced vital capacity (odds ratio [OR] = 2.08; 95% confidence interval [CI]: 1.26-3.43), current FEV < 80% (OR = 1.80; 95% CI: 1.03-3.14), ≥1 severe exacerbation in the previous 12 months (OR = 2.43; 95% CI: 1.48-4.01), and Asthma Control Test score < 25 (OR = 2.30; 95% CI: 1.35-3.92) were independently associated with failure. The score showed an area under the curve of 0.690 (95% CI: 0.633-0.747; P < .05) in the derivation cohort and 0.76 (95% CI: 0.643-0.882; P < .001) in a validation cohort of 114 patients. A score <4.5 implies a low risk of failure (<20%), whereas a score >8 implies a high risk (>40%).
This score can facilitate the prediction of step-down failure before medication taper in patients with well-controlled asthma.
必须确定哮喘患者治疗的最小控制剂量,但降级的结果是不可预测的。
确定与哮喘治疗降级时控制丢失风险相关的因素,并开发一种预测该风险的评分。
进行了一项前瞻性、多中心研究,纳入了病情控制良好的成年哮喘患者。治疗在 12 个月的时间内逐渐增加或减少,以维持哮喘控制。我们确定了临床和功能变量与降级失败之间的关联。最后,我们在一个队列中得出了一个预测控制丢失的评分,并在另一个独立的队列中进行了验证。
该推导队列包括 228 名患者;218 名患者至少完成了一次降级阶段,共评估了 495 次降级阶段。支气管扩张剂后用力呼气量 1 秒(FEV1)/用力肺活量(FVC)<70%的病历记录的肺功能结果(比值比 [OR] 2.08;95%置信区间 [CI] 1.26-3.43)、当前 FEV1<80%(OR 1.80;95% CI 1.03-3.14)、过去 12 个月中≥1 次严重加重(OR 2.43;95% CI 1.48-4.01)和哮喘控制测试评分<25(OR 2.30;95% CI 1.35-3.92)与失败独立相关。该评分在推导队列中的曲线下面积为 0.690(95% CI 0.633-0.747;P<.05),在验证队列中的面积为 114 名患者的 0.76(95% CI 0.643-0.882;P<.001)。评分<4.5 意味着药物减少前降级失败的风险较低(<20%),而评分>8 则意味着失败的风险较高(>40%)。
该评分可有助于预测病情控制良好的哮喘患者在药物减量前的降级失败。